TIDAL-01 is under clinical development by Turnstone Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TIDAL-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TIDAL-01 overview

TIDAL-01 is under development for the treatment of solid tumors, cutaneous, non-cutaneous melanoma, HER2 negative and HER2 positive breast cancer, triple negative breast cancer, metastatic colorectal cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma and metastatic uveal melanoma. The therapy comprise of tumor-infiltrating lymphocytes (TILs). It is developed based on TIDAL platform. It is administered through intravenous and parenteral route.

Turnstone Biologics overview

Turnstone Biologics, a subsidiary of Turnstone Biologics Corp, is a clinical stage biotech company engaged in developing breakthrough cancer immunotherapies and drugs for the treatment of solid tumors. The company is headquartered in Ottawa, Ontario, Canada.

For a complete picture of TIDAL-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.